News und Analysen

Agilent Technologies Inc. (NYSE: A) announced today that the recipient of the 2023 Darlene Solomon Award is Kathryn Wolhuter, Ph.D., a senior postdoctoral researcher studying coronary heart disease

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Tom West to Inogen’s Board of

The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced that David A. Jones Jr. has been elected to serve as Chairman of the Board of Directors

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2023, the period ended February 28, 2023, after the close of the

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023. The purpose of

Agilent Technologies Inc. (NYSE: A) announced today that it has been selected as Instrument Business Outlook (IBO) 2022 Company of the Year. IBO highlighted Agilent's increased growth in revenues

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and

Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), announced today that it has contributed more than $1 million to non-profit

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn

Novocure (NASDAQ: NVCR) today announced the 5^th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for

Waters Corporation’s (NYSE:WAT) companywide commitment to “leaving the world better than we found it” has earned it the number five ranking on the Barron’s 2023 100 Most Sustainable Companies U.S

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it entered into a